鼻NK/T细胞淋巴瘤（NKTCL）是EBV相关性高度恶性肿瘤。EBV microRNA (EBV-miR)可在转录后水平调节宿主细胞基因表达。我们前期研究发现NKTCL p27表达低下并与EBV感染、临床分期和预后有关，EBV在转录后水平抑制p27基因表达。本研究用miR芯片筛出NKTCL高表达EBV-miR，qPCR法验证其表达；蛋白质芯片筛出NKTCL低表达细胞周期抑制基因并用免疫组织化学方法进一步验证，找出目标EBV-miR及其调控的靶基因，分析其与临床分期、肿瘤细胞增殖和预后关系；细胞水平检测目标EBV-miR及其靶基因的生物学功能，动物实验检测阻断目标EBV-miR表达抑制肿瘤演进的可行性。探讨EBV-miR 生物学功能及其致NKTCL分子机制，寻找治疗NKTCL分子靶标。

Nasal NK/T cell lymphoma (NKTCL) is an EBV associated malignant tumor with high aggressive clinical course. EBV microRNA (EBV-miR) can modulate the gene expression of infected cells at post-transcriptional level. Our previous study showed that low expression of p27 protein was detected in NKTCL and associated with EBV infection and clinical stage and prognosis. EBV inhibited p27 gene expression at post-transcriptional level in NKTCL cells. At present study, we detect the EBV-miR expression profile in NKTCL with miR microarray and qPCR method, and investigate the expression of cell cycle inhibited genes in NKTCL using protein microarray and immunohistochemistry method, evaluate the correlation between the expression of EBV-miR and cell cycle inhibited genes, as well as the correlation between the expression of target genes and clinical stage, cell proliferation and prognosis in NKTCL; assure the biological function of the target EBV-miR and genes at cell level; and investigate the role of preventing tumor progression by blocking target EBV- miR expression using implanted tumor model in nude mouse. The purpose of the study is to investigate the biological function and the oncogenesis of EBV-miR in NKTCL, and discover the biomarkers that helpful to treat NKTCL.